VK2 stimulates anticancer activity; thus, we hypothesized that it would increase ABL TKI efficacy in CML cells, particularly those that are resistant to the drug. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.